Skip to content
10-Q

Quarterly Report

VITRO BIOPHARMA, INC.

0001493152-24-009929

← back to feed
Filed
Mar 14, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · Mar 14, 2024 4.46M sh
Long Term Debt Q1 2024 · Jan 31, 2024 $2.97M
Long Term Debt Q1 2024 · Oct 31, 2023 $2.95M
Short Term Debt Q1 2024 · Jan 31, 2024 $825.65K
Short Term Debt Q1 2024 · Oct 31, 2023 $480K
Current Liabilities Q1 2024 · Jan 31, 2024 $7.99M
Current Liabilities Q1 2024 · Oct 31, 2023 $4.85M
Total Liabilities Q1 2024 · Jan 31, 2024 $12.19M
Total Liabilities Q1 2024 · Oct 31, 2023 $9.43M
Current Assets Q1 2024 · Jan 31, 2024 $2.29M
Current Assets Q1 2024 · Oct 31, 2023 $3.18M
Total Assets Q1 2024 · Jan 31, 2024 $7.36M
Total Assets Q1 2024 · Oct 31, 2023 $8.34M
Net Income Q1 2024 · Oct 31, 2023 −$5.4M
Net Income Q1 2024 · Jan 31, 2023 −$1.19M
Shares Diluted Q1 2024 · Jan 31, 2023 4.43M sh
Operating Cash Flow Q1 2024 · Jan 31, 2023 −$949.86K
Stockholders Equity Q1 2024 · Jan 31, 2023 $1.91M
Stockholders Equity Q1 2024 · Oct 31, 2022 $2.84M
Eps Diluted Q1 2024 · Jan 31, 2023 −$0.27
Eps Basic restated Q1 2024 · Jan 31, 2023 −$0.27
Sga Expense Q1 2024 · Jan 31, 2023 $1.42M
Rd Expense Q1 2024 · Jan 31, 2023 $6.83K
Operating Income Q1 2024 · Jan 31, 2023 −$1.15M
Gross Profit Q1 2024 · Jan 31, 2023 $277.52K
Cost Of Revenue Q1 2024 · Jan 31, 2023 $66.51K
Revenue Q1 2024 · Jan 31, 2023 $344.59K